NEW YORK and TORONTO — Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) announced on November 15, 2026, that it will present topline results from its Phase 3 APPROACH study tomorrow. The presentation is scheduled for 8:00 a.m. EDT via a scheduled webcast.
The clinical study evaluates HLP003, a proprietary novel serotonergic agonist (NSA), as an adjunctive treatment for patients suffering from major depressive disorder (MDD). According to a company statement, the results will be shared during the webcast, with an archive to be made available on the company’s Events & Presentations webpage following the session.
Clinical Development and Mechanism
Helus Pharma is a clinical-stage pharmaceutical company focused on developing NSAs—synthetic molecules designed to activate serotonin pathways. The company states these molecules are intended to promote neuroplasticity to address unmet needs in mental health conditions, including depression and anxiety.
The HLP003 candidate, currently in Phase 3 development, has previously received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). In addition to HLP003, the company is advancing HLP004, another proprietary NSA, which is currently in Phase 2 clinical development for the treatment of generalized anxiety disorder.
Corporate Operations and Outlook
Helus Pharma operates across Canada, the United States, the United Kingdom, and Ireland. The company maintains an extensive research portfolio of investigational NSAs aimed at various mental health conditions.
In a cautionary note regarding forward-looking statements, the company indicated that actual clinical and regulatory outcomes may differ from current projections due to various risks. These include the ability to enroll and retain trial participants, the necessity for additional financing, and the regulatory complexities associated with controlled substances.
The company noted that the FDA and Health Canada have not evaluated claims regarding the efficacy of NSAs or the specific candidates HLP003 and HLP004. Investors and observers can access the webcast through the company’s official website or via the link provided in their corporate announcement.
